表紙
市場調查報告書

乳癌診斷、藥物技術:全球市場

Breast Cancer Diagnostic and Drug Technologies: Global Markets

出版商 BCC Research 商品編碼 245536
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
乳癌診斷、藥物技術:全球市場 Breast Cancer Diagnostic and Drug Technologies: Global Markets
出版日期: 2019年11月28日內容資訊: 英文 150 Pages
簡介

全球乳癌診斷及治療藥市場,預計從2019年的209億美元到2024年達到282億美元,期間中為6.2%的年複合成長率。

本報告提供全球乳癌診斷、治療藥市場相關調查,各國資料,全球乳房X光攝影、切片檢查、搭配診斷IVD、治療藥市場上收益的估計,主要市場動態、趨勢、機會,M&A、新產品開發、策略、R&D活動相關考察,及主要企業簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術背景

  • 簡介
  • 乳癌的分類:各類型
  • 乳癌的分子亞型
  • 乳癌的原因,症狀,危險因素
  • 流行病學

第4章 乳癌篩檢計劃

  • 簡介
    • 乳房自我檢驗
    • 臨床乳房檢驗
    • 乳房X光攝影
    • 數位乳房斷層攝影
    • 超音波檢驗
    • MRI (核磁共振影像)
    • BRCA致癌基因變異

第5章 乳癌市場動態

  • 市場成長的促進要素
  • 市場成長的阻礙因素
  • 市場機會

第6章 市場分析:各技術

  • 乳癌診斷市場
  • 技術
    • 乳房X光攝影
    • 全球市場
    • 乳房X光攝影的限制
  • 乳房切片針市場
    • 簡介
    • 全球市場
  • 乳癌預測診斷市場
    • 簡介
    • 預測診斷檢驗
    • 全球市場

第7章 市場分析:各類藥物

  • 概要
  • 乳癌的藥物類別
  • 乳癌市場
    • 代謝拮抗劑
    • 紫杉烷
    • 芳香?抑制劑
    • HER2抑制劑
    • 荷爾蒙療法

第8章 市場分析:各地區

  • 乳癌發病率:各地區
  • 全球市場:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲 (MEA)
    • 南美

第9章 法規情形

  • 法規上的課題
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第10章 專利檢討/新開發

  • 專利檢討
  • 搭配診斷

第11章 醫療費償付形勢

  • 簡介
  • 美國
  • 德國
  • 墨西哥
  • 巴西

第12章 開發平台分析

  • 簡介
  • 乳癌治療開發平台:各階段
  • 乳癌治療開發平台:各企業
    • AbbVie Inc.
    • Array BioPharma Inc.
    • AstraZeneca
    • Belrose Pharmaceuticals
    • Beta Pharma
    • BioMarin Pharmaceuticals
    • CASI Pharmaceuticals Inc.
    • Celgene
    • Celldex Therapeutics
    • Celsion
    • Clovis
    • Eli Lilly
    • Novartis
    • Pfizer
    • Puma Biotechnology
    • Roche
    • Syndax Pharmaceuticals
    • Tesaro Inc.

第13章 競爭情形

  • 主要的乳房X光攝影設備廠商
  • 主要的乳癌治療藥廠商

第14章 企業簡介

  • ABBVIE INC.
  • ABBOTT LABORATORIES
  • ASTRAZENECA PLC
  • ATOSSA GENETICS INC.
  • BRISTOL-MYERS SQUIBB CO.
  • DAKO
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • NANOSTRING TECHNOLOGIES
  • NOVARTIS INTERNATIONAL AG
  • PFIZER INC.
  • PUMA BIOTECHNOLOGY INC.
  • SANOFI S.A.

附錄:簡稱

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC106D

Report Highlights:

The global breast cancer diagnostic and drug market should reach $28.2 billion by 2024 from $20.9 billion in 2019 at a compound annual growth rate (CAGR) of 6.2% for the forecast period of 2019 to 2024.

The drug technology segment of the global breast cancer diagnostic and drug market is expected to grow from $17.9 billion in 2019 to $23.7 billion in 2024 at a CAGR of 5.8% for the forecast period of 2019 to 2024.

The companion diagnostics segment of the global breast cancer diagnostic and drug market is expected to grow from $418.2 billion in 2019 to $1.1 billion in 2024 at a CAGR of 21.4% for the forecast period of 2019 to 2024.

Report Scope:

This report is an update to Breast Cancer Diagnostics and Therapeutics Market Report-HLC106B.

The objective of the current report is to provide readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic developments.

This report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates, the regulatory environment for markers and therapeutics, recent regulatory approvals, current and new technologies, market projections and the market share of key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.

This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.

This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2018 (the base year), 2019 and a forecast for 2024.

Report Includes:

  • 26 data tables and 49 additional tables
  • Brief overview of the global markets for breast cancer therapeutics and drug technologies
  • Analyses of global market trends with data from 2018, estimates for 2019 and projections of compound annual growth rates (CAGRs) through 2024
  • Country specific data and analysis for the U.S., Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, South Africa and MEA
  • Revenue details of the global mammography, biopsy, companion diagnostic IVD, and therapeutic markets by various segments and subsegments
  • Competitive landscape covering key market participants and their market share analysis
  • Information on merger and acquisition details, partnerships and alliances, product launce strategies, pipeline drugs, blockbuster drugs, and other novel drugs development
  • A relevant patent analysis
  • Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Introduction
  • Classification of Breast Cancer by Type
    • Non-invasive Breast Cancers
    • Invasive Breast Cancer
  • Molecular Subtypes of Breast Cancer
    • Luminal A
    • Luminal B Types
    • HER2 Type
    • HER2-Amplified
    • Triple-Negative Breast Cancer (TNBC) or Basal Type
    • Normal-Like
  • Brest Cancer Causes, Indications and Risk Factors
    • Symptoms
    • Breast Cancer Staging
  • Epidemiology
    • United States Breast Cancer Incidence

Chapter 4: Breast Cancer Screening Programs

  • Introduction
    • Breast Self-Examination
    • Clinical Breast Examination
    • Mammography
    • Digital Breast Tomosynthesis
    • Ultrasonography
    • Magnetic Resonance Imaging (MRI)
    • BRCA Oncogene Mutations

Chapter 5: Breast Cancer Market Dynamics

  • Market Drivers
    • Increasing Incidence of Breast Cancer Worldwide
  • Market Restraints
    • Pricing Pressure Experienced by Innovators
    • High Cost Associated with New Drug Development and Clinical Trials
    • Regulatory and Reimbursement Hurdles
  • Market Opportunities
    • Rising Female Population in Asia Pacific
    • Increased Demand for Technology Innovation
    • Technological Advancement in the Drug Sector
    • Emergence of Breast Cancer Predictive Tests
    • Patents at the Verge of Expiry
    • Breast Cancer Therapy: Unmet Needs

Chapter 6: Market Breakdown by Technology

  • Breast Cancer Diagnostics Market
  • Technologies
    • Mammography
    • Global Mammography Market
    • Limitations of Mammography
  • Breast Biopsy Device Market
    • Introduction
    • Global Breast Biopsy Device Market
  • Breast Cancer Predictive Diagnostics market
    • Introduction
    • Predictive Diagnostic Tests
    • Global Breast Cancer Companion Diagnostic Test Market

Chapter 7: Market Breakdown by Drug Class

  • Overview
  • Breast Cancer Drug Classes
  • Breast Cancer Market
    • Antimetabolites
    • Taxanes
    • Aromatase Inhibitors
    • HER2 Inhibitor
    • Hormone Therapy

Chapter 8: Market Breakdown by Region

  • Breast Cancer Incidence by Region
  • Global Market by Region
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa (MEA)
    • South America

Chapter 9: Regulatory Scenario

  • Regulatory Challenges
  • North America
    • U.S. Food and Drug Administration (FDA)
  • Europe
  • Asia-Pacific
    • Japan
    • China
  • South America
    • Brazil

Chapter 10: Patent Review/ New Developments

  • Patent Review
  • Companion Diagnostics
    • Patent Expiration

Chapter 11: Reimbursement Landscape

  • Introduction
  • United States
    • Mammography Reimbursement
    • Biopsy Procedure Reimbursement
    • Breast Cancer Drug Reimbursement
  • Germany
    • Mammography Reimbursement
    • Biopsy Procedure Reimbursement
    • Breast Cancer Drugs Reimbursement
  • Mexico
  • Brazil

Chapter 12: Pipeline Analysis

  • Introduction
  • Pipeline by Phase
    • Phase III
    • Phase II
    • Phase I
  • Pipeline by Company
    • AbbVie Inc.
    • Array BioPharma Inc.
    • AstraZeneca
    • Belrose Pharmaceuticals
    • Beta Pharma
    • BioMarin Pharmaceuticals
    • CASI Pharmaceuticals Inc.
    • Celgene
    • Celldex Therapeutics
    • Celsion
    • Clovis
    • Eli Lilly
    • Novartis
    • Pfizer
    • Puma Biotechnology
    • Roche
    • Syndax Pharmaceuticals
    • Tesaro Inc.

Chapter 13: Competitive Landscape

  • Major Mammography Equipment Market Players
  • Major Breast Cancer Drug Market Players

Chapter 14: Company Profiles

  • ABBVIE INC.
  • ABBOTT LABORATORIES
  • ASTRAZENECA PLC
  • ATOSSA GENETICS INC.
  • BRISTOL-MYERS SQUIBB CO.
  • DAKO
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • NANOSTRING TECHNOLOGIES
  • NOVARTIS INTERNATIONAL AG
  • PFIZER INC.
  • PUMA BIOTECHNOLOGY INC.
  • SANOFI S.A.

Chapter 15: Appendix: Abbreviations

List of Tables

  • Summary Table: Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2024
    • Table 1: Difference between Normal and Benign Breast Cancer Cells
    • Table 2: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017
    • Table 3: Histological Types, Frequency of Occurrence and Rate of Survival
    • Table 4: Mucinous Carcinoma
    • Table 5: Steps and Genes Involved in Breast Cancer Metastasis
    • Table 6: Molecular Subtypes: Invasive Breast Cancer
    • Table 7: Local/Regional Recurrence, by Molecular Subtype
    • Table 8: Local/Regional Recurrence, by Molecular Subtype
    • Table 9: Local/Regional Recurrence, by Molecular Subtype
    • Table 10: Global Breast Cancer Incidence, 2016-2021
    • Table 11: Global Breast Cancer Incidence and Mortality, 2018
    • Table 12: New Breast Cancer Cases and Mortality (both Sexes), by Region, 2018
    • Table 13: New Breast Cancer Cases in the U.S., by Gender, Through 2024
    • Table 14: New Female Breast Cancer Cases and Deaths in the U.S., by Age, 2018
    • Table 15: Mammography Recommendations
    • Table 16: Femara Revenue, 2009-2015
    • Table 17: Generic Versions of Letrazole
    • Table 18: Global Mammography Market, by Region, Through 2024
    • Table 19: Global Mammography Market, by Device Type, Through 2024
    • Table 20: Global Breast Cancer Biopsy Device Market, by Region, Through 2024
    • Table 21: Breast Cancer Prognostics, Diagnostics, Monitoring and Grading Diagnostics Tests, 2017
    • Table 22: Breast Cancer Drugs
    • Table 23: Global Breast Cancer Drug Market, by Drug Class, Through 2024
    • Table 24: Global Aromatase Inhibitor Drug Market, by Drug Type, Through 2024
    • Table 25: Global HER2 Inhibitor Drug Market, by Drug Type, Through 2024
    • Table 26: Global Hormone Receptor Drug Market, by Drug Type, Through 2024
    • Table 27: Global Breast Cancer Therapy Market, by Region, Through 2024
    • Table 28: North American Breast Cancer Therapy Market, by Country, Through 2024
    • Table 29: European Breast Cancer Therapy Market, by Country, Through 2024
    • Table 30: Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2024
    • Table 31: FDA-Approved Drugs, 1996-2019
    • Table 32: List of FDA-Approved Companion Diagnostics, 2018
    • Table 33: Breast Cancer Drugs Approved by the EMA, 1995-2018
    • Table 34: Companion Diagnostics Patent Review, 2015-2017
    • Table 35: Breast Cancer Therapeutics Patent Review, 2010-2018
    • Table 36: Patent Expiration of Breast Cancer Drugs
    • Table 37: Mammography Reimbursement, U.S., 2017
    • Table 38: Biopsy Procedure Reimbursement, U.S., 2017
    • Table 39: Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
    • Table 40: German Mammography In-Patient Reimbursement
    • Table 41: In-Patient Biopsy Procedure Codes
    • Table 42: Gemzar and Herceptin Reimbursement, Germany, 2017
    • Table 43: hase III Breast Cancer Therapy Pipeline
    • Table 44: Phase II Breast Cancer Therapy Pipeline
    • Table 45: Phase I Breast Cancer Therapy Pipeline
    • Table 46: AbbVie Inc.: Pipeline Drugs
    • Table 47: Array BioPharma Inc.: Pipeline Drugs
    • Table 48: AstraZeneca: Pipeline Drugs
    • Table 49: Belrose Pharmaceuticals: Pipeline Drugs
    • Table 50: Beta Pharma: Pipeline Drugs
    • Table 51: BioMarin Pharmaceuticals: Pipeline Drugs
    • Table 52: ASI Pharmaceuticals Inc.: Pipeline Drugs
    • Table 53: Celgene: Pipeline Drugs
    • Table 54: Celldex Therapeutics: Pipeline Drugs
    • Table 55: Celsion: Pipeline Drugs
    • Table 56: Clovis: Pipeline Drugs
    • Table 57: Eli Lilly: Pipeline Drugs
    • Table 58: Novartis: Pipeline Drugs
    • Table 59: Pfizer Inc.: Pipeline Drugs
    • Table 60: Puma Biotechnology: Pipeline Drugs
    • Table 61: Roche: Pipeline Drugs
    • Table 62: Syndax Pharmaceuticals: Pipeline Drugs
    • Table 63: Tesaro Inc.: Pipeline Drugs
    • Table 64: AbbVie Inc.: Company Net Revenue, 2016-2018
    • Table 65: Abbott Laboratories: Company Net Revenue, 2016-2018
    • Table 66: Abbott Laboratories: Marketed Products, 2018
    • Table 67: AstraZeneca PLC: Company Net Revenue, 2016-2018
    • Table 68: AstraZeneca PLC: Marketed Products, 2018
    • Table 69: Bristol-Myers Squibb Co.: Net Revenue, 2016-2018
    • Table 70: Eli Lilly and Co.: Net Revenue, 2016-2018
    • Table 71: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2016-2018
    • Table 72: Novartis International AG: Net Revenue, by Segment, 2016-2018
    • Table 73: Pfizer Inc.: Net Revenue, 2016-2018
    • Table 74: Abbreviations Used in Breast Cancer Diagnostic and Drug Technology

List of Figures

  • Summary Figure: Global Breast Cancer Diagnostic and Drug Market, by Technology, 2018-2024
    • Figure 1: Breast Anatomy of Normal and Cancerous Ducts and Lobules
    • Figure 2: Market Shares of Invasive and Non-invasive Breast Cancer, United States, 2017
    • Figure 3: Histopathological Classification of Breast Cancer
    • Figure 4: Invasive Breast Cancer Market Share, by Type
    • Figure 5: Occurrence of Molecular Subtypes Share
    • Figure 6: Global Burden of Breast Cancer
    • Figure 7: National Cancer Institute Research Funding, 2011-2016
    • Figure 8: NCRI Breast Cancer Research Spending, 2009-2017
    • Figure 9: Mammography Procedures in U.S., Canada and Mexico, 2010-2015
    • Figure 10: Mammography Procedures in Europe, by Country, 2010-2015
    • Figure 11: Mammography Procedures in Asia-Pacific, by Country 2010-2015
    • Figure 12: Global Mammography Market, 2018-2024
    • Figure 13: Global Breast Cancer Drug Market Share, by Drug Class, 2018
    • Figure 14: Global Aromatase Inhibitor Drug Market, by Drug Type, 2018-2024
    • Figure 15: Global HER2 Inhibitor Drug Market, by Drug Type, 2018-2024
    • Figure 16: Global Hormone Receptor Drug Market, by Drug Type, 2018-2024
    • Figure 17: Middle East and African Breast Cancer Therapy Market, 2018-2024
    • Figure 18: South American Breast Cancer Therapy Market, 2018-2024
    • Figure 19: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
    • Figure 20: PMDA Medical Device Approval Procedure
    • Figure 21: Reimbursement of Drugs in Germany
    • Figure 22: Global Market Share of Mammography Equipment, by Company, 2018*
    • Figure 23: Global Market Share of Breast Cancer Drugs, by Company, 2018
    • Figure 24: AbbVie Inc.: Net Revenue, 2016-2018
    • Figure 25: AbbVie Inc.: Lupron Sales, 2016-2018
    • Figure 26: Abbott Laboratories: Revenue Share, by Segment, 2018
    • Figure 27: Bristol-Myers Squibb Co.: Revenue Share, by Region, 2018
    • Figure 28: Bristol-Myers Squibb Co.: Revenue Share, by Business Segment, 2018
    • Figure 29: Eli Lilly and Co.: Revenue Share, by Region, 2018
    • Figure 30: F. Hoffmann-La Roche Ltd.: Pharmaceutical Revenue Share, by Business Segment, 2018
    • Figure 31: F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue, 2016-2018
    • Figure 32: F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue Share, by Region, 2018
    • Figure 33: Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2018
    • Figure 34: Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017
Back to Top